Teva Pharmaceutical Industries Limited (NYSE:TEVA) Insider Sells $423,263.25 in Stock

Teva Pharmaceutical Industries Limited (NYSE:TEVA) insider Eric A. Hughes sold 24,537 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the sale, the insider now owns 45,060 shares in the company, valued at $777,285. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Teva Pharmaceutical Industries Stock Down 0.7 %

TEVA opened at $16.79 on Thursday. The firm’s 50-day simple moving average is $16.80 and its 200-day simple moving average is $14.86. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries Limited has a twelve month low of $8.06 and a twelve month high of $18.02. The firm has a market cap of $19.02 billion, a price-to-earnings ratio of -40.95, a PEG ratio of 1.49 and a beta of 0.90.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.03). The company had revenue of $3.82 billion during the quarter, compared to analyst estimates of $3.70 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Clal Insurance Enterprises Holdings Ltd grew its position in shares of Teva Pharmaceutical Industries by 7.1% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock worth $342,788,000 after buying an additional 2,188,212 shares during the period. Meitav Investment House Ltd. grew its position in shares of Teva Pharmaceutical Industries by 82.8% during the 4th quarter. Meitav Investment House Ltd. now owns 4,305,674 shares of the company’s stock worth $44,914,000 after buying an additional 1,950,500 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Teva Pharmaceutical Industries by 6.9% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock worth $301,920,000 after buying an additional 1,860,000 shares during the period. Maple Rock Capital Partners Inc. grew its position in shares of Teva Pharmaceutical Industries by 68.3% during the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after buying an additional 1,770,000 shares during the period. Finally, Glenview Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $16,752,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on TEVA shares. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Piper Sandler restated an “overweight” rating and set a $20.00 price target (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd. Finally, Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Wednesday, July 10th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.